HC Wainwright Issues Pessimistic Estimate for CMPX Earnings

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for Compass Therapeutics to a loss of $0.15 per share from $0.11, while maintaining a Buy rating and $24 price target.
• Compass reported a quarterly loss of $0.13 per share, missing the $0.11 consensus estimate by $0.02. Analysts overall remain moderately bullish, with a consensus price target of $11.77.
• CMPX shares opened at $2.15, near the lower end of their 52-week range of $1.61 to $6.88, while institutional investors own 68.43% of the company.

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Investment analysts at HC Wainwright cut their Q3 2026 earnings estimates for Compass Therapeutics in a research report issued on Thursday, August 6th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.15) for the quarter, down from their previous forecast of ($0.11). HC Wainwright currently has a "Buy" rating and a $24.00 target price on the stock. The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Compass Therapeutics' Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.55) EPS, FY2027 earnings at ($0.56) EPS and FY2028 earnings at ($0.56) EPS.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02).

Several other research analysts have also recently weighed in on CMPX. Stifel Nicolaus set a $6.00 target price on Compass Therapeutics in a report on Monday, June 1st. LADENBURG THALM/SH SH initiated coverage on shares of Compass Therapeutics in a report on Wednesday, July 1st. They issued a "buy" rating and a $5.00 target price on the stock. Piper Sandler increased their price target on shares of Compass Therapeutics from $4.00 to $6.00 and gave the company an "overweight" rating in a research note on Friday. Citizens Jmp restated a "market outperform" rating and set a $10.00 price target on shares of Compass Therapeutics in a report on Tuesday, April 28th. Finally, Canaccord Genuity Group reduced their price target on shares of Compass Therapeutics from $13.00 to $7.00 and set a "buy" rating on the stock in a research report on Tuesday, April 28th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $11.77.

Compass Therapeutics Price Performance

Shares of CMPX opened at $2.15 on Monday. The stock has a market cap of $387.19 million, a PE ratio of -5.37 and a beta of 0.92. Compass Therapeutics has a 52-week low of $1.61 and a 52-week high of $6.88. The firm's fifty day moving average is $2.09 and its two-hundred day moving average is $3.85.

Institutional Trading of Compass Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Suvretta Capital Management LLC increased its position in shares of Compass Therapeutics by 0.6% during the fourth quarter. Suvretta Capital Management LLC now owns 14,182,379 shares of the company's stock valued at $76,159,000 after acquiring an additional 81,220 shares during the last quarter. BlackRock Inc. purchased a new stake in shares of Compass Therapeutics in the 2nd quarter valued at approximately $24,707,000. Vivo Capital LLC lifted its holdings in shares of Compass Therapeutics by 57.9% in the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company's stock worth $33,409,000 after acquiring an additional 3,502,000 shares during the last quarter. BVF Inc. IL lifted its holdings in shares of Compass Therapeutics by 63.5% in the 4th quarter. BVF Inc. IL now owns 7,764,842 shares of the company's stock worth $41,697,000 after acquiring an additional 3,014,842 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Compass Therapeutics by 45.6% during the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company's stock worth $24,720,000 after purchasing an additional 2,212,794 shares during the period. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source